Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Stomatitis? 2,560 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 2,560 reports of Stomatitis have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 6.5% of all adverse event reports for CABOZANTINIB S-MALATE.

2,560
Reports of Stomatitis with CABOZANTINIB S-MALATE
6.5%
of all CABOZANTINIB S-MALATE reports
91
Deaths
347
Hospitalizations

How Dangerous Is Stomatitis From CABOZANTINIB S-MALATE?

Of the 2,560 reports, 91 (3.6%) resulted in death, 347 (13.6%) required hospitalization, and 8 (0.3%) were considered life-threatening.

Is Stomatitis Listed in the Official Label?

Yes, Stomatitis is listed as a known adverse reaction in the official FDA drug label for CABOZANTINIB S-MALATE.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Death (2,504)

What Other Drugs Cause Stomatitis?

METHOTREXATE (7,245) TOCILIZUMAB (4,761) ADALIMUMAB (4,500) LEFLUNOMIDE (4,492) ABATACEPT (4,481) ETANERCEPT (4,338) RITUXIMAB (4,335) CERTOLIZUMAB PEGOL (3,760) INFLIXIMAB (3,713) PREDNISONE (3,656)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Stomatitis Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Stomatitis Reports All Drugs Causing Stomatitis CABOZANTINIB S-MALATE Demographics